CHICAGO, November 24, 2015 /PRNewswire/ --
Molecular Dynamics will present its revolutionary whole body CZT digital SPECT/CT solution at the upcoming 101st Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) taking place in Chicago on Nov-29th through Dec-4th, in Booth 1122, Hall A.
The company will introduce the Valiance X12 system, a breakthrough improvement over the currently available general purpose analog SPECT technology. The Valiance X12 delivers high resolution, low dose, high speed personalized images, based on a unique imaging platform and proprietary imaging algorithms designed to deliver results comparable to PET at a lower cost.
"We are excited about the introduction of the Valiance X12 at RSNA" said Mr. Din Hadass, Molecular Dynamics Israel's COO. "Innovative features including adaptive image acquisition that focuses the detectors on specific organs, combined with simultaneous multiple isotope and online dynamic imaging capabilities allow the Valiance X12 to tailor the imaging process to individual patients and collect more data from each scan."
The advanced features, combined with superior accuracy at high count rates are designed to enable unprecedented absolute quantification for therapy planning and monitoring. The system simultaneously improves image quality, scan time and patient dose.
"Our innovative CZT-based technology and advanced applications will provide physicians with cost-effective personalized-medicine solutions, leading to more accurate diagnoses and, ultimately, better clinical outcomes," said Professor Shlomo Ben-Haim, Founder of Molecular Dynamics.
About Molecular Dynamics
Molecular Dynamics, a member of the Hobart Group companies, is developing innovative imaging technologies and advanced clinical applications. The company's whole body functional imaging system, based on CZT technology, simultaneously improves image quality, scan time and patient dose. When used together with its novel applications, Valiance X12 will enable improved diagnosis and treatment-optimization and monitoring, resulting in more cost-effective treatments and better clinical outcomes. For more information visit http://www.molecular-d.com.
About the Hobart Group
The Hobart Group accelerates ideas and develops and commercializes medical technologies, targeting top healthcare markets with significant unmet needs. Its growing portfolio of companies covers the fields of cardiology, diabetes, oncology, neurology and rehabilitation. Together, Hobart Group companies employ over 200 scientists, engineers, regulatory and business experts across four continents, benefitting from the group's financial strength, clinical expertise and extensive international market knowledge across Europe, the US and Asia. For more information please visit http://www.hobart-group.com.
Mrs. Sharon Alon
Email: [email protected]
SOURCE Molecular Dynamics